Trial Profile
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in Patients With Advanced Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 23 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Sep 2020 Planned End Date changed from 31 Mar 2022 to 30 Sep 2022.
- 23 Jun 2020 Results, data as of cut off date March 20, 2020 for safety and efficacy analysis, published in the Lancet Oncology